Shares of Nutex Health Inc. (NUTX.O) experienced a notable increase today, crossing above its 5-day simple moving average (SMA) as investor confidence surged following the company's impressive financial results. For the third quarter of 2025, Nutex reported total revenue of $267.8 million, a staggering 239.9% increase year-over-year, alongside a net income of $55.4 million, marking a significant turnaround from a loss in the same period last year. This robust performance was primarily driven by the hospital division, which alone generated $260.2 million, reflecting strong operational growth and demand for its services. The company has also regained compliance with Nasdaq listing requirements, further enhancing its market position as it prepares to discuss its financial results in an upcoming conference call.
Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 265.00 USD with a low forecast of 230.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 265.00 USD with a low forecast of 230.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 149.800
Low
230.00
Averages
265.00
High
300.00
Current: 149.800
Low
230.00
Averages
265.00
High
300.00
Maxim
Maxim
Buy
downgrade
$225 -> $205
2025-08-26
Reason
Maxim
Maxim
Price Target
$225 -> $205
AI Analysis
2025-08-26
downgrade
Buy
Reason
Maxim lowered the firm's price target on Nutex Health to $205 from $225 and keeps a Buy rating on the shares. On August 14th, the company filed an NT 10-Q notification of inability to timely file its 10-Q for the three months ended 6/30/25, due to the incorrect accounting classification of certain non-cash obligations, the analyst tells investors in a research note. The firm views the accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD, as potential headwinds to the stock price, Maxim added.
Maxim
Maxim
Buy
maintain
$100 -> $225
2025-05-20
Reason
Maxim
Maxim
Price Target
$100 -> $225
2025-05-20
maintain
Buy
Reason
Benchmark
Buy
upgrade
$150 -> $300
2025-05-15
Reason
Benchmark
Price Target
$150 -> $300
2025-05-15
upgrade
Buy
Reason
Benchmark raised the firm's price target on Nutex Health to $300 from $150 and keeps a Buy rating on the shares based on "another big beat" in Q1 and positive updates to the firm's model. Based on greater visibility into the sustainability of rate arbitration success realization, the firm is "significantly lifting" its FY25 and FY26 outlooks for revenue, adjusted EBITDA and GAAP EPS, the analyst tells investors, adding that Nutex remains a "Benchmark Best Idea."
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$75 → $100
2025-04-08
Reason
Maxim Group
Anthony Vendetti
Price Target
$75 → $100
2025-04-08
Maintains
Strong Buy
Reason
Maxim raised the firm's price target on Nutex Health to $100 from $75 and keeps a Buy rating on the shares. The company delivered significantly better-than-expected Q4 results, driven largely by the company's success in achieving improved reimbursement by advancing claims through the No Surprises Act's IDR - independent dispute resolution - process, the analyst tells investors in a research note. Beyond IDR activity, Nutex continues to advance its core growth strategy, with its hospitals expanding service lines to treat higher-acuity patients and to drive increased inpatient and observation visit volumes, the firm adds.
About NUTX
Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization (MSO), it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
